Stockreport

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Exclusive agreement covers 13 Central and Eastern European marketsCollaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive A [Read more]